ESG goals

Dear investors and clients:

We are very happy to announce that our team is now establishing and building an initiative devoted for ESG (Environmental, Social and Governance). We focus ESG industry, we consider ESG Criteria in our investment targets. We believe it is impossible to be a responsible participant in today’s society without paying attention to ESG. Our team believes in financially compelling opportunities in ESG which will also drive value to investors. We are proudly committed and invested with our time and patience in discovering and standing behind these opportunities knowing our hearts in a good place.

The green energy and sustainable business will take lead for the future growth at lease 10-15 years. According to the Paris Agreement, its goal is to keep global warming considerably below 2 degrees Celsius, preferably 1.5, compared to pre-industrial levels.

Countries aspire to reach global peaking of greenhouse gas emissions as soon as possible to produce a climate neutral world by mid-century to meet this long-term temperature objective.

The Paris Pact is a watershed moment in the international climate change process because it is the first time that a legally binding agreement binds all nations together in a common cause to fight climate change and adapt to its repercussions.

By 2020, although huge increases in climate change action are required to meet the Paris Agreement's goals, the years since its coming into force have already spawned low-carbon solutions and new markets. Carbon neutrality targets are being set by an increasing number of governments, regions, cities, and businesses. Zero-carbon solutions are becoming more competitive across a variety of economic sectors that account for 25% of total emissions. This trend is especially obvious in the electricity and transportation sectors, and it has opened a slew of new business opportunities for those who get in early. By 2030, zero-carbon solutions may be competitive in industries that account for more than 70% of world emissions. We are still far from the goals! There are many opportunities for us to make the change for the world!

We will focus on the three points of our business related to the Paris Agreement: Finance, Technology, and Capacity-Building.

Finance:

The Paris Agreement maintains that affluent countries should lead in providing financial support to less developed and vulnerable countries, while also encouraging voluntary contributions from other Parties for the first time. Because large-scale expenditures are necessary to considerably cut emissions, climate finance is required for mitigation. Climate finance is also critical for adaptation, as large financial resources are required to adjust to the negative effects of climate change and mitigate its consequences.

Technology:

The Paris Agreement outlines a goal of fully implementing technological development and transfer in order to improve climate change resilience while also lowering GHG emissions. It establishes a technological framework to provide overarching guidance to the Technology Mechanism's efficient operation. Through its policy and implementation arms, the mechanism is increasing technology development and transfer.

Capacity-Building:

Many of the issues posed by climate change are beyond the capabilities of many developing countries. As a result, the Paris Agreement places a strong emphasis on developing nations' climate-related capacity-building efforts and calls on all wealthy countries to increase their assistance for such efforts.

In order to make the world better than just have maximum profits, T&J brothers group will continue to make the impact for the world and try our best to fight with climate change.

Thank you.

Sincerely,

James

Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

David Barthel on the left, photo taken by Marizyme, inc staff.

Source: Marizyme Inc.

JUPITER, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Executive Officer for Marizyme. In his role Mr. Barthel will look to advance the Company’s technology pipeline and stay committed to the commercialization efforts of DuraGraft in Europe and Asia while focusing on the FDA submissions for DuraGraft and MATLOC 1 in the US. In addition, Mr. Barthel will lead the Company through its financing initiatives, strengthening the financial position of the Company in preparation for an anticipated Nasdaq listing in 2022.

Mr. Barthel founded The SmartPill Corp. and led the company as CEO & President until its acquisition by medical device giant, Medtronic. Mr. Barthel successfully took The SmartPill company, developing an innovative ingestible sensor-based capsule for diagnosing GI motility disorders, from its initial patent, through the entire product development process, raising more than $70 million in multiple funding rounds. Mr. Barthel led his team through multiple clinical trials, manufacturing, FDA approval, commercialization and successful insurance reimbursement.  After the acquisition by Medtronic, Mr. Barthel joined the company as Area Vice President, GIH Southeast Division.

Most recently, Mr. Barthel was CEO of Health Logic Interactive Inc. (“Health Logic”) and its wholly owned Subsidiary, My Health Logic Inc. (“My Health Logic”), a company focused on developing an innovative point-of-care lab-on-chip digital diagnostic device technologies for chronic kidney disease.  In less than a year, Mr. Barthel led the Company from an initial patent pending technology with proof-of-concept data to building an IP portfolio and further advancing our lab-on-chip technology platform. The Company also began development on its point-of-care device, MATLOC 1, which is expected to have a functional prototype ready for its clinical trials to take place in Q3 2022. Mr. Barthel was responsible for implementing product and software development partners, the preparation of an FDA pre-submission, leading discussions with several potential strategic partners, integrating a strong clinical and business team-based culture, and a diverse Scientific Advisory Board. He has also developed the business plan around the utilization of multiple partners for commercialization with the potential for multiple revenue streams that will ensure eventual success of the device. My Health Logic Inc., subsidiary of Health Logic which holds the MATLOC device technology and all accompanying agreements, is currently in the process of being acquired by Marizyme.

Mr. Barthel earned a Bachelor of Arts Degree from St. Norbert College in De Pere, Wi and an MBA from Lake Forest Graduate School of Management in Lake Forest, II.

Dr. Vithal Dhaduk, (Chairman) of the Board of Directors, stated the following: “We are very excited about acquiring My Health Logic and David Barthel becoming our CEO. My Health Logic developed the MATLOC technology, an innovative technology that has strong potential to improve the lives of millions of patients with chronic kidney disease.  Bringing on the very dedicated and effective management group led by David Barthel will add strength to Marizyme's current team.

This is a very strategic step for Marizyme to diversify and improve Marizyme's current product portfolio by adding more innovative, platform technologies and a strong management team. We are looking forward to bringing these new technologies to the market to serve a unique and unmet need in the chronic kidney and cardiac disease population."  

(PR) Health Logic Interactive Signs Non-Binding Letter of Intent With US Medical Device Company to Sell Wholly Owned Operating Subsidiary

TSXV: CHIP.H

CALGARY, AB, Aug. 9, 2021 /PRNewswire/ - Health Logic Interactive Inc. ("Health Logic" or the "Company") (TSXV: CHIP.H) (OTCPK: CHYPF) is pleased to announce it has signed, on August 1, 2021, a non-binding letter of intent to sell its wholly owned operating subsidiary, My Health Logic Inc. ("My Health Logic") to Marizyme, Inc. ("Marizyme"), a Nevada medical device company publicly traded on the OTCQB (the "Transaction").

The transaction is subject to the completion of diligence, the approval of the TSX Venture Exchange, negotiation of definitive documentation, and approval of the Company's shareholders. The transaction is taking place at arms-length, and it is currently expected that the consideration for all the issued and outstanding shares of My Health Logic will be common shares in the capital of Marizyme.

Marizyme has a robust IP portfolio for its medical device platform technologies. Its leading technology, DuraGraft®, is currently under pre-submission review with the United States Food and Drug Administration ("FDA"). Durgraft is approved in 34 countries and has already achieved initial commercial sales in Europe and Asia. Marizyme intends to pursue a listing on the NASDAQ Stock Market ("NASDAQ") within the next twelve months.

The proposed terms, which are subject to change as diligence and negotiations progress, include:

• The Company receiving 4,600,000 shares of Marizyme as consideration for the Health Logic asset. The number of shares was negotiated between parties of Marizyme and Health Logic, and the price per share is a floating number that will be finalized in the definitive agreement.

• Marizyme plans to raise the necessary operating capital for the combined businesses once the transaction has taken place, from there, a registration and anticipated financing on a Nasdaq listing.

• My Health Logic will become a wholly owned subsidiary of Marizyme;

• The Company will have the right to appoint two nominees to the board of directors of Marizyme; it is expected that the management of Marizyme will change once the transaction is completed.

• The employees of, and consultants to, My Health Logic will continue to operate in the same capacity as prior to the Transaction; and

• The Transaction is subject to the negotiation and execution of definitive documentation, the performance of any closing conditions, and TSXV and shareholder approvals.

The Company will continue to trade as a public entity on the NEX Board of the TSXV and intends to pursue a financing to commence its search for new assets to develop as part of the Company's portfolio. The Company plans to continue its application with the TSXV for a reactivation to Tier 2 of the TSXV from the NEX Board. The reactivation will be subject to finding of a new acquisition target and meeting all continued listing requirements of the TSXV Tier 2.

The Company will hold a conference call to discuss the Transaction in more detail, the conference call is scheduled to occur on August 16, 2021, at 1.30pm PST / 4.30pm EST. Please dial in toll free at 1-866-248-8441 or internationally at 1-323-289-6581.

Quote from CEO, David Barthel:

"As we have demonstrated over the past eight months, the team has the ability to accomplish its milestones as we continue to deliver on our initial goals in the clinical development of our lab-on-chip technology. These accomplishments have attracted strong interest from several potential strategic partners. Our team is pleased to be presented with this Transaction that will, if completed, allow My Health Logic to receive the necessary resources to advance its lab-on-chip technology. As well, Marizyme has a very attractive medical device pipeline that is already on an FDA pathway, is a US publicly traded entity, and is supported by a full-service US investment bank, Univest Securities.  We have moved quickly to assess this Transaction and complete initial due diligence, and are excited about the prospects at hand".

About the Company

Health Logic Interactive, through its wholly owned operating subsidiary My Health Logic, is developing and commercializing consumer focused handheld point-of-care diagnostic devices that connect to patient's smartphones and digital continued care platforms. The Company plans to use their patent pending lab-on-chip technology to provide rapid results and facilitate the transfer of that data from the diagnostic device to the patient's smartphone. The Company expects this data collection will allow it to better assess patient risk profiles and provide better patient outcomes. Our mission is to empower people with the ability to get early detection anytime, anywhere with actionable digital management for chronic kidney disease. For more information visit us at: www.healthlogicinteractive.com

About Marizyme, Inc.

Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortality and costs in the acute care space. The Company's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft® enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft® is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease based therapeutic Krillase® platform. Krillase® is not approved for use.

Further information regarding Health Logic Interactive Inc. and its disclosure documents are available on SEDAR at www.sedar.com.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notes

Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the execution of a definitive agreement for the Transaction and the terms thereof, the completion of the Transaction and its expected benefits, the financing to be provided by Marizyme, the listing of the Marizyme Shares on the NASDAQ, the financing to be pursued by the Company, the reactivation of the Company to the TSXV and the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's Management's Discussion and Analysis for the year ended December 31, 2020. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law.

SOURCE Health Logic Interactive Inc.

Related Links

https://www.healthlogicinteractive.com/

Thank you letter!

What is investment? - Chinese language

什么是投资？投资到底怎么赚钱的？投资的好处是什么？每个人都适合投资吗？许许多多的问题最近都在我脑子里。 其实，我觉得投资者更多的时候应该是在思考而不是操作。很多时候一次性赚一百万不如每天一百块。许多人都希望一夜暴富，我也希望，但是我知道这个是不可能的事情。每一次和客户的交谈，我尽可能的希望他们能够投资投资。当然不是所有人都喜欢我，即使你是世界上最有名的明星，也会有人讨厌你。没关系，我吸取教训，下次再接再厉。如果有信任的客户，我会对他们更加的关照，因为他们的信任是我最大的荣誉。我当然不能辜负了他们的信任。

接下来聊聊投资。对我来说投资就是投的未来。用合适的价格来买公司未来的价值。投资股票，就是投资公司，你可以反对，也可以不相信我，但是，投资真正的真谛就是公司本身，这也是股票出现的价值。所以，当我们买入一家公司的时候，就是买入这家公司的价值。他会升值，相对于公司拥有者就会赚钱。它会贬值，那么我们的投资就会缩水。这就是投资的真谛。

投资的好处是什么？很简单，当投资人睡觉的时候，钱也在增值。这就是投资的好处，它可以给你带来你能力所达不到的回报（但是你的眼光和公司分析能力一定要好）。 投资，可以让我们了解不同的行业，了解不同的知识，学习到更多的文化。这也是我作为投资者的目的。我不停的投资，我也不停地学习。

很多人问我，是不是每个人都适合投资。我的回答是不是。为什么我说不是。投资不仅仅是公司的投资。我们的人生也是投资。学习是对未来的投资，朋友是对生活的投资，运动是对身体的投资。所以不是每个人都能把握好投资的真谛。如果你不能够爱上这门艺术，你应该交给爱的人帮你去做。你可以用心做你喜欢的事情，让钱赚钱就去交给更厉害的人做。其实很多基金经理，他们的目的就是赚钱，对我来说，我希望去投资改变世界的公司，比如特斯拉，医疗，新能源。很多人问我，我能够了解吗。我会给你说，我不了解但是我喜欢，所以我愿意去学习，我愿意花时间去了解。我本不是一个爱看书的人，但是因为投资，我喜欢上了看书，我喜欢上了运动。我和父母的感情更加友好。我更加珍惜我的父母。 短期的投资，以及投机。我不反对。不过对我来说投资者应该把投资的本质看得更加清楚，更加明确。当我们决定了的事情，就要一心一意做到底。投资，是一场无形的战场，也是培养士兵的军营。我们就是指挥官，去寻找，去培养，最好的士兵。

Never invest in a business you can't understand

It is essential to understand the value of the company. Many people ask me at the conference that what do you think about private equity or hedge fund. I will say, realize what do you buy, and know the value of the company. Many people believe investing is so simple, and some people think it is tough to understand. To me, it is straightforward for financing, but it is very hard for understanding. We need to understand the business before we put the money into the market. There are many ways to study and learn the company, such as a financial report, management team, and business culture. For example, many people love the iPhone, and they all know if we want to make money in the market, buy Apple company stock shares. How many people own the Apple stocks have ever take a look at their financial report. Many people know it is an excellent company, but they don't know their financial statements. Maybe it was a good company last year, and its revenue is decreasing this year. Then, if an investor bought its stocks last year, they will lose money next year even if everyone said it is a very good company, and many people love their products. Many people know how much to buy the iPhone, but very few people know how much cost for an iPhone. The investor must understand the company and make sure they understand how the company makes money and how much money they make. For my speech at the December finance conference, I said many times that investors should know what they own. They can't make money by not knowing the company. They shouldn't call themselves investors; they are spectacular. Too often people invest in stocks market without a clue as how a company generates revenue, cost expenses, and produces profits. Only investor can make money from understanding the economic process of the company. That’s what Warren Buffett called “intelligent investor”.

Also, investor should understand the history of the company. "This time is different." This sentence probably cost most stock market investors far more than they know. Indeed, every period of time is different. Nonetheless, we can learn from history a lot of lessons that should guide how we invest today. Failure to learn from other people's past mistakes can be detrimental to your property. The history will tell people if the company was truthful company, and also if the company was keeping the promising. When there is company promise to achieve their goal five years ago and they didn’t reach it, then there is big probability they will fail this time again. In almost all aspects of human behavior and thought, history repeats itself, in that way, economic cycles replicate themselves. Basically, a financial market is the result of millions of collective human thoughts / behaviors shown on a price chart. You can use some of the collective thought. Many people think this time will be different. In inside of system, there are many things similar to each other. For example, fear and greedy. So, understand the business is very important in investing.

There are some questions that I could help people to understand the company more:

Is the business simple and understandable?

Does the business have favorable long-term prospects?

Does the business have strongly negative debt issue?

Does the business have a consistent operating history?

Is management work with shareholders?

What’s the business’s return on equity?

We could focus on many ways to understand the business in business aspect, management aspect, and financial aspect.

“Heavy is the head who wears the crown."

The one trying to wear the crown must withstand the weight.

From Shakespeare:

“Canst thou, O partial sleep, give thy repose
To the wet sea-boy in an hour so rude,
And in the calmest and most stillest night,
With all appliances and means to boot,
Deny it to a king? Then happy low, lie down!
Uneasy lies the head that wears a crown.
Uneasy lies the head that wears a crown.”

欲戴其冠，必承其重。这句话早是出自于莎士比亚的文章里。这次我的主题会以这句话来写。为什么我会用中文来写这篇文章？因为，目前而言，这个问题普遍出现在亚洲地区，特别是快速发展的经纪形式，比如抖音。 网络媒体的出现造就了许许多多的红人。比如网络主播，网络网红，以及自媒体。非常好的趋势，这样可以让更多的人学到只是，也会让更多的人出人头地，成名成功。 当然，这不是一个好事。很多人问我为什么成名成功不是一件好事？你有钱了，你有名了想做什么都可以啊，压力也少了。当然就像开头我说的，你带了这个王冠，就必须承受王冠的重量。

最好的例子就是网红，简称网络红人。很多人都想成为网红，但是你真的意识到后面的艰苦与奋斗吗。不是那么简单去当一个网红，发一张照片有几万个人点赞。既然你想成为网红，你就要承受其带来的压力（网络压力）。会有人喜欢你，就会有人不喜欢你。你总不能让所有人都喜欢你吧。拿着网红所带来的优势，却不想有人批评你，或者承受不了别人的批评，那么就不要去做这个行业。你是明星，大家都会关注你，然后你想要别人的关注，又想有平常人的隐私，这是非常难办到的。当你成为了明星，赚了许许多多的钱，然后反过来说你没有隐私每个人都关注着你，这就是一个非常矛盾的思想。

在这世界上，每个事情的背后都会有一个花费。任何事情都会付出了才会得到。我一个朋友是华尔街投资银行的老总。之前和他聊天，他给我看过一个他的日程表两个月跑了27个城市，分别4个国家，大概2天一个城市而且中间只有一天的休息。他赚了很多钱但是赚钱的背后就是付出。那么有些人问我，懒人可以不付出啊。错了！一样你要付出，那么就是你需要承受别人可以享受的生活，而你不行。别人在奋斗工作，你在家玩着游戏喝着啤酒。那么你就要承受别人可以去各种地方旅游，而你只能在家待着。或许你并不觉得这个是一个付出，其实这是，这样子来说吧当你因为喝酒而身体健康出现了问题，这就是你的花费，而别人每天健身的人就可以有一个良好的身体。当然他也付出了，在你休息喝酒吃着自己喜欢的甜品的时候，他，正在挥洒汗水，抑制自己的贪婪，这也是他的付出！

对于我们的事业，要选一个自己喜欢的能够一直做下去的行业，当然你也要了解这个行业的辛苦与汗水。我自己在做投资，在做私募，我既然选择了这个我就要去了解他，学习他。我在大学的时候就开始投资股票，一心想着别人赚钱赚得好多好厉害，满脑子都是这样的想法都没有好好去学习。我付出的就是我的金钱。我亏掉了很多，因为我不去学习他不去了解他。就拿私募举个例子，每一个项目都是不一样的公司，公司的背后就是学习的知识，向我这样一个新兴管理者我需要做的就是每一个项目我都要去了解他。危险在哪，未来的路在哪，我也要去学习会计，财务报表以及管理学。这家公司到底能不能管理好，以及这家公司的财务会不会有大问题。很多人觉得你是基金经理不需要去了解这些，但是往往这就是决定成败的原因。并不是仅仅给钱就是了。特斯拉和未来汽车都是一样的想法，都筹集了非常多的资金，但是一个成功，一个失败。很多时候我们不仅仅要从成功者学习经验。还去失败的公司了解他们失败的原因。就算现在给你一个亿，你或许也不能成功的留住这笔资金。所以每个路，都要去好好的走，都要好好的坚持，因为每一个选择背后都是付出。

每个人都会做出选择，而你，需要为你的选择付出努力，任何选择都是需要付出的，及时你的懒惰，你的贪婪，也都会标上价格。没有一切是免费的。我也希望大家能够好好地选择自己的路，欲戴其冠，必承其重。

投资的精神 Spirit of investment

               这一次我会用中文写一篇想法。 因为这个想法更多的影响到中国人的投资观念。 整篇文章会围绕着一句话来讲：“慢慢的有钱，仔细的分析。”现在的潮流是一些快节奏的生活。当然不是指“快节奏”，而是“快赚钱”。 比如我们耳熟能详的抖音，自媒体的火热，游戏的主播。当时各种爆火的游戏主播以及所谓的抖音网红确确实实让很多人富有了起来，也让许多人找到了出路。这些“快节奏致富”帮助非常多的人改变了他们的生活以及家人。但是，随着时间的推移，目前我们耳熟能详的人都消失不见了，为什么呢？因为这是快节奏赚钱的后果。 捷径，许许多多的人都喜欢走捷径，因为他们可以付出较少的努力而获得大的成就但是问题就在于能否持续这样的方式。美国非常火的零售店“forever 21”-永远二十一，今年签了破产保护。曾经世界各地女生都喜欢的时尚品牌落到了需要去申请破产保护而且当我走进商店时他们几乎所有的商品都在打折促销，即使这样去的人也不是特别多。是什么造就了一些巨型的成功又如何失败的？ 这些都与投资以及“慢慢的赚钱，仔细的分析”有关系。

               现在这个时候，大家都想一夜暴富，通过抖音让自己出名，通过自媒体让自己成为明星，但是都忽略了背后的付出以及事业的苦难。太多人的看到Facebook的创始人20几岁就成功了，或者一些拍抖音的美女也是一夜走红，他们一夜成名，成为了大家关注的焦点。很多人就看到了这样的成功而开始眼红。自己为什么不能像他们一样一夜就成名。或许明天我就是大家关注的焦点，或许明天我就会去小巨蛋开演唱会，或许明天我走在路上就可以遇到经纪公司和我签约。 但是大家都忘记了一个巨大的问题，也是财富背后的问题，那就是付出。

               任何事情都需要有付出，做一个懒人要付出，做一个记者要付出，做一个明星要付出，做一个投资人要付出。他们都会有不同的付出，让我来讲讲不同的成功所需要不同的付出吧。举个简简单单的例子，明星，许许多多得人觉得我当了明星我就是有钱人所有的人都会来关注我。 当然，非常准确，而且背后的付出就是你很难有自己的隐私，这就是公众人物的问题。你想成文公众人物，但是又不想为之所付出那是不肯能的。作为懒人，有基本的工作，不想去减肥，不想付出，那么你就会有健康问题。不想有健康问题那就需要花时间去运动，也需要忍住垃圾食品的诱惑。所以任何事情都会有个“付出或者花费”。巨大的财富所需要的就是慢慢的积累，慢慢的成功。巴菲特是一个非常好的例子，巴菲特从小就喜欢赚钱当然也非常喜欢存钱（重点知识！！存钱）。 巴菲特的投资理念非常的简单，那就是：找一个很好地公司长期持有它。为什么这么简单的问题大家都成功不了。因为他需要花时间，需要投资人好好地分析公司（这就是非常大的学问，找到好的公司，我之后会和大家讲解），需要投资人有耐心去了解公司并且以一个非常低的价格买入，但是这些所有的一切都需要时间。不是一年，不是两年，而是一辈子。我在3年前采访霍华德马克思（橡树投资公司的创始人），他问过我一个问题，你是否是真正的喜欢投资。我说：是的，我非常的喜欢。 但是他立刻否定了我的回答，因为我的年轻，我的经历我还不能说真正的喜欢投资。要经历失败并且不放弃它才叫做真正的喜欢。巴菲特几十年的投资没有放弃过。我们或许可以看到许多人想要退休想要出去玩，这就好好的证明他们并不是真正的喜欢。时间是一个很好地朋友。我有个基金经理好朋友叫做“Robert”他非常的聪明（他持有特斯拉在特斯拉最低的时候 不仅没有卖出还大量的持有，当然他分析特斯拉这家公司用了快1000个小时）。他当时说过是不是好的投资者时间可以证明一切。 现在许多成功的网红，有钱的主播慢慢的褪去了当年的光环，他们一时的富有并不能持久。所以“慢慢的成功，仔细的分析”才是投资的最好的策略。

Fake investor VS Real investor ---- where your money goes matters to you.

The reason I want to write this article about real and fake investors because I see too many fake investors call themselves expert and “educated wealth manager”. It is so sad for people who believe how fake smart they are and loss people’s money again and again. However, they don’t lose money at all because they will charge their clients management fee and get money from that. Many hedge fund and private equity manager will charge 2% management fee even when they have bad performance on market.

Most people will go to school and learn stock market or trading class about investment bank such as M&A. However, 90% of school’s teachers don’t have real experience in stock market or never work with investment bank ever. How can they teach investment? And how could people learn from them? I will give a very good example of trading stock market and fake teacher vs real teacher. Many teachers will tell you to try paper trading which is fake money and image people buy stocks to avoid making mistake. However, good wealth managers are learning from their mistake like Ray Dalio and Peter Lynch. If we don’t make mistake how could we learn from trading and avoid making same mistake to be better? This is fake teacher. Another point is about emotions. Real money and fake money will treat investor different because you probably will lose your lunch meal for next week because you can’t hold your emotions and scared to lose all your or your parents’ money. Fake teacher will lead fake students. And fake students will become future fake wealth managers.

 I started trading stocks three years ago and still make a lot of mistakes. Even Ray Dalio went bankrupt when he was 30 years old. We are humans. We will make mistake, and this is how we could learn more knowledge from our mistakes and change it then make it better.

From the beginning, we think we know more things than we know. Then, we will make mistake and we notice that our actual knowledge. Then we will study it and learn from the mistake and make it better. This is how real-life learning and studying circle. Most people just avoiding mistake and keep move to another part, but they will make the same mistake again and again.

This is the biggest gap between real investors and fake investors. Learning, most hedge fund managers and private equity managers don’t study from their mistake. They try to avoid it and they don’t try to change it. My weakness is financial report. Then, I try to read one report every week and find the most important information in the company’s report and study for it. I am not saying that I am real investor. However, I study hard for my mistake and my weakness. Also, I will keep posting my thoughts on the market and my personal investing life with people.

Diversify--- the investment of my life

This is my second article of my thought thru my time. This time, I want to talk more about investment of diversify. Why we want to diversify our investment? “Don’t put all your eggs to one basket.” This is very famous phrase in Wall Street. Before Wall Street people use it for getting more commission fees because they can make people buy more different stocks and they could have more commission fees for themselves. As the time goes by, diversity is becoming more important strategy for investment. We all know the trade war between China and America. The trade war makes a deep decrease for both Chinese and American stocks and economy. This is very sad news for both. We don’t like that. However, we can’t stop it, and nobody can image this will happen when Trump become the president of the United State.

The trade war between China and America will have good result for both countries. I strongly hold my positive attitude for it. As a Chinese living in America, I wish good for both countries. We will figure it out by win-win situation for the trade war. However, when market is uncertain, we could use diversity investment strategy to avoid big lose for our investment. Many investors are not actually investors (I will explain this in future articles). For example, when Chinese stocks go up, American stock market go down. If investor only hold American stock, they will lose money. However, if investor hold both country stocks, they may get even return or maybe a little profit if up more than down. In my company, we are investing in equity (stocks and bond), we also investing in filming such as bridge loan for secure investment return to make sure we could make profit for our investors.

There are some different investments:

Stocks in the United States. Companies of different sizes should be included. The price of the business is measured by market capitalization. Include in each portfolio small-cap, mid-cap, and large-cap.

Fixed income from the U.S. The best is the United States. Treasuries and shares for savings. The federal government provides these. There are also very secure municipal bonds. You can also purchase short-term bond funds and money market funds invested in these protected securities. Corporate bonds offer higher yields with higher risk. Junk bonds provide the highest returns and risk.

Stocks from abroad. These include both established and emerging-market firms. When you spend domestically, you can achieve greater diversification. International investment can yield higher returns as emerging markets grow faster. But they are more risky investments because they have less central bank guarantees in place, they can be vulnerable to political change.

For our company, we do investment in equity, real estate and loan for filming industry. We diversify our investment to reach highest return and lowest risk for our investor. If there are big and absolute investment, I strongly suggest putting all the bet on that. However, for most people, we could diversify and investment different and more as we can.